Sign up to save your podcasts
Or
Share European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.
We dived into several key studies that are shaping the future of lung cancer treatment, including:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.
Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.
YouTube: https://youtu.be/akoXXAUEl_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.
We dived into several key studies that are shaping the future of lung cancer treatment, including:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.
Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.
YouTube: https://youtu.be/akoXXAUEl_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
290 Listeners
White Coat Investor Podcast
2,428 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
188 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners